Amsterdam UMC research meeting with the Executive Board on International, multicenter randomized drug trials initiated by investigators at Amsterdam UMC.
Amsterdam institute for Immunology and Infectious diseases
Initiation of international, multicenter randomized drug trials is definitely a challenge. What are the opportunities and pitfalls?
Program:
1. Prof. dr. Maarten Boers (Epidemiology & Data Science - Rheumatology – Amsterdam institute for Infection and Immunity – Amsterdam Public Health)
Experience with the GLORIA trial (EU-Horizon 2020):
double blind randomized trial comparing prednisolon vs placebo in elderly patients with rheumatoid arthritis; 8 countries; 451 patients.
2. Dr. Hanneke Wilmink (Medical Oncology – Cancer Center Amsterdam)
Experience with the NAPAN trial:
Randomized trial comparing the combination of liposomal irinotecan and 5-FU vs liposomal irinotecan and S1 in patients with metastasized pancreas carcinoma, after prior treatment based on gemcitabin; 5 countries, 130 patients.
3. Leonie Middelink, M.Sc. (Independent Clinical Research Executive - Middelinc)
Update current and expected regulations, findings of National Health and Youth Care Inspectorate (Inspectie Gezondheidszorg en Jeugd) and possibilities
4. Discussion
Start date: | |
---|---|
Time: | |
End time: | |
Location: | Online via Teams |
Costs: | Free of charge. An Amsterdam UMC e-mail account is required for participation. The Teams-link does not work within CDW or View. Send the link to your private mail and open outside CDW. Tip for MAC-users: Teams works better in Google Chrome does not work within CDW or View. Send the link to your private mail and open outside CDW. Tip for MAC-users: Teams works better in Google Chrome |
---|
Organisor |
Research Support Amsterdam UMC |
|
---|---|---|
Contact | Leonie van Duivenvoorde | l.m.vanduivenvoorde@amsterdamumc.nl |